脂肪性肝炎-话题@MedSci

#脂肪性肝炎#

121篇内容 | 3338人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1956107, encodeId=4755195610ec4, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Nat Commun：双阴性T细胞抑制非酒精性脂肪性肝炎的发生发展, objectType=article, longId=206921, objectId=cf67206921e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf67206921e3, replyNumber=0, likeNumber=96, createdTime=2022-01-19, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf67206921e3, moduleTitle=Nat Commun：双阴性T细胞抑制非酒精性脂肪性肝炎的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf67206921e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956094, encodeId=984f195609466, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善, objectType=article, longId=196884, objectId=c1dc196884ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1dc196884ba, replyNumber=0, likeNumber=73, createdTime=2020-12-24, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1dc196884ba, moduleTitle=非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1dc196884ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956081, encodeId=9f281956081bd, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J Hepatology：法尼醇X受体激动剂对非酒精性脂肪性肝炎患者脂蛋白谱的影响, objectType=article, longId=186945, objectId=51681869456c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51681869456c, replyNumber=0, likeNumber=71, createdTime=2020-03-06, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51681869456c, moduleTitle=J Hepatology：法尼醇X受体激动剂对非酒精性脂肪性肝炎患者脂蛋白谱的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51681869456c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956097, encodeId=b7fb195609ede, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, objectType=article, longId=197999, objectId=2c2219e999bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2219e999bb, replyNumber=0, likeNumber=74, createdTime=2020-11-07, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2219e999bb, moduleTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c2219e999bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956105, encodeId=49fe1956105c7, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效, objectType=article, longId=203466, objectId=48e120346625, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48e120346625, replyNumber=0, likeNumber=66, createdTime=2021-09-09, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48e120346625, moduleTitle=非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48e120346625)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956082, encodeId=919419560822b, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J Hepatology：微生物群导致的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提, objectType=article, longId=186947, objectId=9d2e18694e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d2e18694e78, replyNumber=0, likeNumber=73, createdTime=2020-08-11, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d2e18694e78, moduleTitle=J Hepatology：微生物群导致的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d2e18694e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956095, encodeId=8709195609516, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定, objectType=article, longId=197673, objectId=890919e6737a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890919e6737a, replyNumber=0, likeNumber=0, createdTime=2021-03-01, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890919e6737a, moduleTitle=非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890919e6737a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956088, encodeId=ef1d1956088c5, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Lancet：非酒精性脂肪性肝、非酒精性脂肪性肝炎以及肝纤维化的鉴别新机制, objectType=article, longId=190440, objectId=aeda1904409e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeda1904409e, replyNumber=0, likeNumber=117, createdTime=2020-07-28, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeda1904409e, moduleTitle=Lancet：非酒精性脂肪性肝、非酒精性脂肪性肝炎以及肝纤维化的鉴别新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeda1904409e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956099, encodeId=75dc195609981, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J Hepatol: Maddrey评分<32分且病理提示存在脂肪性肝炎的酒精性肝病患者长期预后特点, objectType=article, longId=199716, objectId=2d7d199e16c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d7d199e16c8, replyNumber=0, likeNumber=63, createdTime=2021-02-18, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d7d199e16c8, moduleTitle=J Hepatol: Maddrey评分<32分且病理提示存在脂肪性肝炎的酒精性肝病患者长期预后特点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d7d199e16c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956074, encodeId=233619560e464, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著, objectType=article, longId=182880, objectId=6912182880b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6912182880b4, replyNumber=0, likeNumber=71, createdTime=2020-06-28, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6912182880b4, moduleTitle=Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6912182880b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956085, encodeId=6c60195608591, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Intern Med：非酒精性脂肪性肝炎患者自身免疫性胃炎高发, objectType=article, longId=189314, objectId=5e51189314c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e51189314c0, replyNumber=0, likeNumber=69, createdTime=2020-06-23, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e51189314c0, moduleTitle=Intern Med：非酒精性脂肪性肝炎患者自身免疫性胃炎高发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e51189314c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956098, encodeId=4de91956098d2, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, objectType=article, longId=198731, objectId=37c9198e311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37c9198e311c, replyNumber=0, likeNumber=70, createdTime=2020-08-27, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37c9198e311c, moduleTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37c9198e311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956078, encodeId=89bf19560e8bf, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J hepatology：Emricasan在治疗非酒精性脂肪性肝炎（NASH）肝硬化合并门脉高压中患者中的疗效, objectType=article, longId=185405, objectId=309b18540526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=309b18540526, replyNumber=0, likeNumber=65, createdTime=2020-07-22, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=309b18540526, moduleTitle=J hepatology：Emricasan在治疗非酒精性脂肪性肝炎（NASH）肝硬化合并门脉高压中患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=309b18540526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956083, encodeId=f0031956083da, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Lancet Gastroen Hepatol：非侵入性高风险非酒精性脂肪性肝炎患者识别方法, objectType=article, longId=187430, objectId=e81d18e43040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e81d18e43040, replyNumber=0, likeNumber=59, createdTime=2020-09-09, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e81d18e43040, moduleTitle=Lancet Gastroen Hepatol：非侵入性高风险非酒精性脂肪性肝炎患者识别方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e81d18e43040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956087, encodeId=5699195608ed8, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=J Gastroenterology：身体代谢情况与非酒精性脂肪性肝炎与严重纤维化之间的关联 , objectType=article, longId=189575, objectId=4cba1895e540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cba1895e540, replyNumber=0, likeNumber=81, createdTime=2020-05-29, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cba1895e540, moduleTitle=J Gastroenterology：身体代谢情况与非酒精性脂肪性肝炎与严重纤维化之间的关联 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cba1895e540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956079, encodeId=31c019560e93e, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Diabetes Care：2型糖尿病患者非酒精性脂肪性肝炎的经济和临床负担, objectType=article, longId=185881, objectId=6fa118588156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fa118588156, replyNumber=0, likeNumber=94, createdTime=2020-12-06, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fa118588156, moduleTitle=Diabetes Care：2型糖尿病患者非酒精性脂肪性肝炎的经济和临床负担, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fa118588156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956092, encodeId=6dfb195609253, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点, objectType=article, longId=196006, objectId=cc5f1960069e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc5f1960069e, replyNumber=0, likeNumber=67, createdTime=2021-01-26, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc5f1960069e, moduleTitle=非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc5f1960069e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956080, encodeId=df5a1956080ff, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎, objectType=article, longId=186009, objectId=83751860095e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83751860095e, replyNumber=0, likeNumber=64, createdTime=2020-10-25, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83751860095e, moduleTitle=Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83751860095e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956084, encodeId=1ba519560849f, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=AP&T：严重肥胖和非酒精性脂肪性肝炎患者的血浆代谢改变情况, objectType=article, longId=188220, objectId=dd2e18822005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd2e18822005, replyNumber=0, likeNumber=56, createdTime=2020-11-17, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd2e18822005, moduleTitle=AP&T：严重肥胖和非酒精性脂肪性肝炎患者的血浆代谢改变情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd2e18822005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1956086, encodeId=9c3c1956086c6, content=<a href='/topic/show?id=8a048435058' target=_blank style='color:#2F92EE;'>#脂肪性肝炎#</a>, objectTitle=Zydus Cadila的PPAR激动剂saroglitazar在印度获批，用于治疗非酒精性脂肪性肝炎, objectType=article, longId=189572, objectId=17961895e2f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17961895e2f5, replyNumber=0, likeNumber=79, createdTime=2020-03-10, rootId=0, userName=Tamikia, userId=66e52500008, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17961895e2f5, moduleTitle=Zydus Cadila的PPAR激动剂saroglitazar在印度获批，用于治疗非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17961895e2f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

脂肪性肝炎

2020-05-29

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Nat Commun：双阴性T细胞抑制非酒精性脂肪性肝炎的发生发展

2022-01-19

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善

2020-12-24

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J Hepatology：法尼醇X受体激动剂对非酒精性脂肪性肝炎患者脂蛋白谱的影响

2020-03-06

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败

2020-11-07

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效

2021-09-09

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J Hepatology：微生物群导致的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提

2020-08-11

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定

2021-03-01

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Lancet：非酒精性脂肪性肝、非酒精性脂肪性肝炎以及肝纤维化的鉴别新机制

2020-07-28

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J Hepatol: Maddrey评分<32分且病理提示存在脂肪性肝炎的酒精性肝病患者长期预后特点

2021-02-18

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著

2020-06-28

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Intern Med：非酒精性脂肪性肝炎患者自身免疫性胃炎高发

2020-06-23

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）

2020-08-27

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J hepatology：Emricasan在治疗非酒精性脂肪性肝炎（NASH）肝硬化合并门脉高压中患者中的疗效

2020-07-22

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Lancet Gastroen Hepatol：非侵入性高风险非酒精性脂肪性肝炎患者识别方法

2020-09-09

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

J Gastroenterology：身体代谢情况与非酒精性脂肪性肝炎与严重纤维化之间的关联

2020-05-29

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Diabetes Care：2型糖尿病患者非酒精性脂肪性肝炎的经济和临床负担

2020-12-06

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

非酒精性脂肪性肝炎（NASH）迎来新进展：lanifibranor达到期中研究的主要终点

2021-01-26

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Northsea Therapeutics融资4000万美元开发鱼油衍生物，治疗非酒精性脂肪性肝炎

2020-10-25

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

AP&T：严重肥胖和非酒精性脂肪性肝炎患者的血浆代谢改变情况

2020-11-17

Tamikia (审核中...)

前往app查看评论内容

#脂肪性肝炎#

Zydus Cadila的PPAR激动剂saroglitazar在印度获批，用于治疗非酒精性脂肪性肝炎

2020-03-10

科室
- - 订阅+
  - 更多科室
工具
服务